KFDA nods ACT based wound healing therapy

The Korea Food and Drug Administration said it has approved a new autologous cell therapy (ACT) developed by S. Biomedics, a local biopharmaceutical company.

Autologous material can be utilized as both a stand-alone treatment or in composite with other materials, according to a company official.

Composites that utilize synthetic or allogeneic components are also being employed for growth ...